Q1 25 EPS
$-0.82
BEAT +9.90%
Est. $-0.91
Q1 25 Revenue
$22.1M
BEAT +105.88%
Est. $10.7M
vs S&P Since Q1 25
+242.9%
BEATING MARKET
KYMR +276.1% vs S&P +33.2%
Market Reaction
Did KYMR Beat Earnings? Q1 2025 Results
Kymera Therapeutics posted a quarter defined more by pipeline momentum than by its headline financials, as the clinical-stage biotech reported Q1 2025 revenue of $22.10 million and a loss of $0.82 per share, with collaboration income more than doubli… Read more Kymera Therapeutics posted a quarter defined more by pipeline momentum than by its headline financials, as the clinical-stage biotech reported Q1 2025 revenue of $22.10 million and a loss of $0.82 per share, with collaboration income more than doubling year-over-year thanks to a $20.00 million milestone payment from Sanofi tied to the IRAK4 program. The net loss widened to $65.58 million from $48.56 million in Q1 2024, as R&D spending surged to $80.25 million, reflecting the company's accelerating bet on its STAT6 and newly unveiled IRF5 degrader programs. The headline development was the debut of KT-579, a first-in-class oral IRF5 degrader showing greater than 90% target degradation preclinically, with Phase 1 expected in early 2026. Meanwhile, the lead STAT6 asset KT-621 is tracking toward Phase 2b trials in atopic dermatitis and asthma by late 2025 and early 2026, respectively. A strategic decision to discontinue the TYK2 program KT-295 extended the company's cash runway into H1 2028, backed by $775.00 million on hand, though some analysts have flagged the shifting pipeline priorities as a source of near-term uncertainty.
Key Takeaways
- • Sanofi collaboration milestone payment of $20 million drove majority of Q1 2025 collaboration revenue increase
- • Increased R&D investment in STAT6 and TYK2 degrader programs, platform and discovery programs
- • Interest income of $8.9 million from cash and investment portfolio partially offset operating loss
KYMR YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
KYMR Revenue by Segment
With YoY comparisons, source: SEC Filings
“The Kymera team continues to advance our first-in-class pipeline on the path to revolutionizing the treatment of complex immuno-inflammatory diseases. We are making tremendous progress across our programs and approaching key near term inflection points. In June, we will be sharing the KT-621 healthy volunteer data for our STAT6 program, an important milestone in the development of this franchise. Additionally, we recently initiated, well ahead of schedule, patient dosing in the KT-621 BroADen Phase 1b study, with data in the fourth quarter of this year. This is another important inflection point as we rapidly progress KT-621 toward later-stage studies.”
— Nello Mainolfi, Q1 2025 Earnings Press Release
KYMR Earnings Trends
KYMR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
KYMR EPS Trend
Earnings per share: estimate vs actual
KYMR Revenue Trend
Quarterly revenue: estimate vs actual
KYMR Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.85 | $-0.71 | +16.07% | $34.4M | +317.57% |
| Q4 25 MISS FY | $-0.79 | $-0.97 | -23.10% | $2.9M | -80.61% |
| FY Full Year | $-3.47 | $-3.69 | -6.46% | $39.2M | -26.90% |
| Q3 25 MISS | $-0.79 | $-0.94 | -19.50% | $2.8M | -88.06% |
| Q2 25 MISS | $-0.80 | $-0.95 | -19.12% | $11.5M | -52.51% |
| Q1 25 BEAT | $-0.91 | $-0.82 | +9.90% | $22.1M | +105.88% |